



Pharma **POOL**

Christopher **CLEMENT**

Savient Pharmaceuticals
Names CEO

Savient Pharmaceuticals has named Christopher Clement CEO, in addition to his role as president. Savient, East Brunswick, N.J., is engaged in developing, manufacturing, and marketing pharmaceutical products that address unmet medical needs in both niche and wider markets. He joined the company in May 2002 as president and chief operating officer.

Mr. Clement also has been appointed to the position of acting chairman, pending the completion of recommendations from the nominating and corporate governance committee of the board as to a permanent chairperson. Mr. Clement succeeds Sim Fass, who has retired.

Dr. John C. **LECHLEITER**

Gino **SANTINI**

Lilly Announces Senior
Leadership Changes

Eli Lilly, Indianapolis, has named John C. Lechleiter, Ph.D., executive VP of pharmaceutical operations. Mr. Lechleiter's role, which encompassed pharmaceutical product development as well as pharmaceutical operations, now includes the added direct responsibility of Lilly's U.S. pharmaceutical business.

Mr. Lechleiter joined Lilly in 1979, and his experiences include roles in pharmaceutical product development, project management, and regulatory affairs.

Gino Santini has been named senior VP for corporate strategy and policy. In this new role, Mr. Santini has responsibility for corporate strategy, business development, alliance management, corporate affairs, and a newly created office of access and pricing.

Mr. Santini joined Lilly in 1983 and has held various positions in affiliate offices around the world as well as in corporate strategy and business development.

Biotech **POOL**

James A. **COUR**

Aastrom Biosciences Appoints
President and COO

Aastrom Biosciences, Ann Arbor, Mich., has appointed James A. Cour president and chief operating officer, a newly created position. Mr. Cour is responsible for the day-to-day operations of the company, which develops proprietary stem cell-based products for the regenerative repair of damaged human tissues and other medical disorders.

Before joining Aastrom, he held executive-level management positions with several companies, including Baxter International, Windsor VanGelder, and Cytomedix.

Mr. Cour received a B.A. with honors from the University of Notre Dame, and a MBA from the University of Chicago, with concentrations in marketing and international business and a specialization in finance. He also is licensed as a certified public accountant.

Dr. Willard **DERE**

Dr. Brian **KOTZIN**

Dr. Joshua **OFMAN**

Amgen Names VPs

Amgen has appointed Willard Dere, M.D., to the position of VP and head of general medicine. He formerly headed the inflammation therapeutic area.

Dr. Dere leads general medicine, a new therapeutic area for the biotechnology company consisting of bone, metabolism, nephrology, neurology, cardiology, and endocrinology.

Before joining Amgen, Thousand Oaks, Calif., Dr. Dere was VP of endocrine, bone, and general medicine research and development at Eli Lilly.

He received his medical and undergraduate degrees from the University of California at Davis.

Brian Kotzin, M.D., has been appointed to the position of VP and head of the inflammation therapeutic area. Dr. Kotzin directs the global development efforts for all new Amgen product candidates in the inflammation area.

He has joined Amgen from the University of Colorado Health Sciences Center in Denver, where he served as head of clinical immunology in the Department of Medicine and as director of the Autoimmunity Center of Excellence.

Dr. Kotzin received his medical degree from Stanford and undergraduate degree in mathematics from the University of Southern California. He is board certified in rheumatology and internal medicine.

Joshua Ofman, M.D., M.S.H.S., has been named to the new position of VP of reimbursement and payment policy. He is responsible for the design and execution of Amgen's reimbursement and payment strategy.

He joined Amgen in 2003 as senior director, U.S. medical affairs, and head of Amgen's U.S. health economics and outcomes research group.

Dr. Ofman obtained his undergraduate degree from the University of California at Berkeley and his M.D. from the University of California, Irvine College of Medicine. He conducted his internship and residency in internal medicine and fellowship in digestive diseases at the University of California, Los Angeles (UCLA) Department of Medicine. In addition, Dr. Ofman completed a RAND/VA/UCLA fellowship in ambulatory care and health services research, specializing in technology assessment, and received a master of science in health services from the UCLA School of Public Health.

Dr. Daniel J.

O'SHANNESSEY

Chief Operating Officer Position
Created at Targeted Diagnostics &
Therapeutics

Targeted Diagnostics & Therapeutics (TDT), a biotechnology company developing molecular-based technologies for the targeted detection, diagnosis, and treatment of gastrointestinal cancers and infectious diseases, has appointed Daniel J. O'Shannessy, Ph.D.,

to the position of chief operating officer. Dr. O'Shannessy also is responsible for overseeing the strategic growth and evolution of the biotechnology company's new products and technologies.

Dr. O'Shannessy has joined TDT, West Chester, Pa., from Gen-Probe, where he served as senior director of strategic planning, oncology diagnostics.

Dr. O'Shannessy received his B.Sc., biochemistry, and B.Sc., honors biochemistry, degrees from the University of Queensland, Australia, and his Ph.D. in biochemistry from the University of Auckland, New Zealand.

Dr. Martha **VINCENT**

Agensys Names Clinical R&D President

Agensys has appointed Martha Vincent, Ph.D., F.A.C.C.P., as VP of clinical research and development. Dr. Vincent brings extensive expertise in clinical, regulatory, and medical affairs to Santa Monica, Calif.-based Agensys, a biotech company developing therapeutic monoclonal antibodies to treat solid-tumor cancers.

Dr. Vincent has joined Agensys from Amgen where she served in different clinical and medical affairs positions during her 17-year tenure, most recently as VP of medical affairs.

Biopharmaceutical **POOL**

Dr. James E. **BARRETT**

Adolor Appoints Chief Scientific Officer

Adolor has named James E. Barrett, Ph.D., chief scientific officer. Dr. Barrett also serves as president of research. Adolor, Exton, Pa., is a biopharmaceutical company specializing in the discovery, development, and commercialization of prescription pain-management products.

Most recently, Dr. Barrett served as president, research and development, at Memory Pharmaceuticals where he oversaw all exploratory, discovery, preclinical, and clinical research and development activities for the company.

He has published more than 275 scientific articles, books, and abstracts in the areas of neuropharmacology, neurobiology, and neuroscience. He recently was elected president of the American Society for Pharmacology and Experimental Therapeutics for the 2005 term.

Dr. Barrett earned his Ph.D. in psychology and neurobiology from Pennsylvania State University.

Dr. William J. **BOYLE**

Chief Scientific Officer Named at Auxeris Therapeutics

Auxeris Therapeutics, a biopharmaceutical company focused on the development and commercialization of medicines to treat a broad range of bone diseases, has appointed William J. Boyle, Ph.D., as chief scientific officer to lead the development of several drug candidates for the prevention of osteoporosis and the treatment of bone metastases.

Before joining St. Louis-based Auxeris, Dr. Boyle led experimental research platforms at Protein Pathways as VP of biology.

He received his bachelor's and master's degrees in biology from UCLA and a doctoral degree in experimental pathology from the UCLA School of Medicine.

Dr. M. Timothy **COOKE**

AVANT Expands Senior-Management Team

AVANT Immunotherapeutics has named M. Timothy Cooke, Ph.D., as senior VP of commercial development. AVANT Immunotherapeutics, Needham, Mass., discovers, develops, and sells innovative vaccines and therapeutics that harness the human immune system to prevent and treat disease.

Dr. Cooke leads the strategic marketing function, including market assessments and analysis, evaluating the company's product portfolio, developing global commercialization strategies, and providing input to partnering strategies. In addition, Dr. Cooke has responsibility for overall project management at a corporate level, directing cross-functional project teams, and managing project time lines.

Dr. Cooke has joined the company from Mojave Therapeutics, where he was CEO. He received a B.S. from Saint Joseph's University, a Ph.D. from Columbia University in bioorganic chemistry, and a MBA from Columbia Business School.

Dr. Gregory

DAVENPORT

Geoff **GREEN**

DOR BioPharma Announces Management Changes

Ralph M. Ellison, M.D., has resigned as president, CEO, and a director of Miami-based DOR BioPharma and its subsidiaries. DOR BioPharma is a biopharmaceutical company focused on the development of biodefense vaccines and therapeutics for areas of unmet medical need.

Gregory Davenport, Ph.D., formerly VP of business development, has been promoted to the newly created position of president of the company's biodefense division.

Geoff Green, formerly chief operating officer of the company, has been promoted to the position of president and acting CEO.

Dr. Michael J. **MURRAY**

Memory Pharmaceuticals Names Head of Preclinical Drug Development

Memory Pharmaceuticals has named Michael J. Murray, Ph.D., VP of preclinical drug development. Memory Pharmaceuticals is a biopharmaceutical company located in Montvale, N.J., that is focused on developing innovative drugs for the treatment of debilitating central nervous system disorders.

He has joined Memory Pharmaceuticals from Praecis Pharmaceuticals where he held the position of VP of preclinical drug safety.

Dr. Murray received his Ph.D. and M.S. degrees from the University of California, Davis. In addition, he holds a B.A. in chemistry and a B.S. in biology from the University of California, Riverside.

Specialty **POOL**

Dr. Daniel **BURKHOFF**

Thomas **CASEY**

Mary Ellen **FREDDO**

Francis H. **MURPHY**

Zafiris G. **ZAFIRELIS**

Biopure Restructuring Results in Management Changes

As part of Biopure's restructuring process Zafiris G. Zafirelis, 59, has been appointed president and CEO and a member of the board. Biopure develops, manufactures, and markets intravenously administered pharmaceuticals, called oxygen therapeutics, that deliver oxygen to the body's tissues.

He brings to the Cambridge, Mass.-based company more than 18 years of experience at the CEO level. Mr. Zafirelis previously was CEO of MedQuest Products.

In line with the reorganization, the company has announced a new strategic focus on cardiovascular disease. Mr. Zafirelis has formed an interim operating team to assist

with the transition process in the clinical, regulatory, and operations functions. Included in this team are Daniel Burkhoff, M.D., Ph.D., a cardiologist/physiologist and adjunct associate professor at Columbia University, who brings expertise in designing and executing clinical trials in cardiology; Thomas Casey, a former partner at Ernst & Young and a healthcare company chief financial officer, who has experience in corporate restructurings; and Mary Ellen Freddo, a regulatory expert with more than 20 years of experience managing FDA submissions for biological products and therapeutics.

In addition, Francis H. Murphy, who had served as Biopure's interim CEO since February 2004, has resumed the position of chief financial officer. He replaces Ronald F. Richards, who is leaving the company. Chief Medical Officer Douglas M. Hansell, M.D., also has resigned.

Dr. Robin D. **CAMPBELL**

Former Amgen Executive Fills SinusPharma CEO Role

SinusPharma, a developer of new therapies for patients with chronic sinusitis, has appointed Robin D. Campbell, Ph.D., as president, CEO, and a member of the board. Dr. Campbell replaces John Wilczak, a founder who remains a member of the board.

Before joining SinusPharma, Carpinteria, Calif., Dr. Campbell was a consultant specializing in commercialization strategy.

Previously, he was with Amgen for 13 years, where he held various positions, including VP of the oncology business unit, VP of Asia-Pacific, and senior director of product development.

He holds a Ph.D. in microbiology and immunology from Wake Forest University and a bachelor's degree from the University of North Carolina at Chapel Hill.

Dr. James V. **CASSELLA**

Industry Veteran Joins Alexza as R&D Head



Alexza Molecular Delivery has named James V. Cassella, Ph.D., as senior VP of research and development of the Palo Alto, Calif.-based specialty company.

Dr. Cassella, a 15-year industry veteran, most recently was senior VP of clinical research and development at Neurogen.

He received a Ph.D. in physiological psychology from Dartmouth College and a B.A. from the University of New Haven.

Dr. Jerry **MCMAHON**

NeoRx's CEO Takes Over Chairman Role

NeoRx, a Seattle-based cancer therapeutics development company, has appointed Jerry McMahon, Ph.D., as chairman. Dr. McMahon was named NeoRx's CEO in May 2004 and continues to serve in that position.

He succeeds Jack L. Bowman, who retired as chairman and CEO in May. Dr. McMahon's appointment to the board increases the number of directors from six to seven.

Dr. Ronald J. **TRANCIK**

R&D VP Named at SkinMedica

SkinMedica, a specialty pharmaceutical company developing and commercializing dermatology products, has named Ronald J. Trancik, Ph.D., VP of research and development.

Dr. Trancik is responsible for all Carlsbad, Calif.-based SkinMedica's product-development initiatives, including the company's pharmaceutical and cosmeceutical products, and assessing potential in-license candidates. Along with company founder Dr. Richard E. Fitzpatrick, Dr. Trancik also works with clinical opinion leaders in the dermatology arena and represents the company at clinical meetings.

Before joining SkinMedica, Dr. Trancik held senior director positions in research and development at Pharmacia and Pfizer.

Dr. Trancik earned his Ph.D. in organic chemistry and M.S. in chemistry from the University of Illinois and his undergraduate degree in chemistry from Wayne State University.

Dr. Andrew

UPRICHARD

EPIX Appoints President and Chief Operating Officer



EPIX Medical, a developer of pharmaceuticals for magnetic resonance imaging, has appointed Andrew Uprichard, M.D., as president and chief operating officer.

Dr. Uprichard brings to EPIX, Cambridge, Mass., more than 15 years experience in drug development. Most recently, he was chief operating officer of ArQule.

Dr. Uprichard holds MB, ChB, and M.D. degrees from The University of Edinburgh, Scotland, and is a fellow of both the Royal College of Physicians of the United Kingdom and the American College of Physicians.

Drug-Delivery **POOL**

Dr. Alan F. **JOSLYN**

Penwest Appoints R&D VP



Alan F. Joslyn, Ph.D., has joined Penwest Pharmaceuticals, an oral drug-delivery company located in Danbury, Conn., as senior VP of research and development. In this position, Dr. Joslyn is responsible for clinical operations, regulatory affairs, pharmaceutical development, and technology research.

Dr. Joslyn, 45, most recently served as VP of internal medicine at Johnson & Johnson Pharmaceutical Research & Development.

Dr. Joslyn has a B.A. in biology, a B.S. in medicinal chemistry, and a Ph.D. in biochemical pharmacology from the State University of New York at Buffalo.

Dr. V. Bryan **LAWLIS**

Aradigm CEO Position Filled Through Promotion

Aradigm has promoted V. Bryan Lawlis, Ph.D., to the position of president and CEO from his previous post of president and chief operating officer. Aradigm's chairman and former CEO, Richard Thompson, remains chairman of the board of the Hayward, Calif.-based drug-delivery company.

Dr. Lawlis has more than 20 years of senior management experience in the biotechnology and pharmaceutical industries and, since joining Aradigm in 2001, has been responsible for leading the day-to-day operations of the company. Before joining Aradigm, Dr. Lawlis was a founder of Covance Biotechnology Services.

He holds a B.A. in microbiology from the University of Texas and a Ph.D. in biochemistry from Washington State University.

Device/Diagnostic **POOL**

Tim **HANSEN**

Imaging Diagnostic Systems Appoints CEO

Imaging Diagnostic Systems, Plantation, Fla., a leader in the field of medical optical imaging, has appointed Tim Hansen as CEO.

Mr. Hansen replaces Linda B. Grable, founder and CEO, who retired in April.

Mr. Hansen has served in top-level executive positions in the medical-imaging industry during a 30-year period, most recently serving as general manager of the radiation management services at Cardinal Health.

Dr. Suzanne
MATTINGLY

Exagen Appoints VP to Establish Strategic Business Relationships



Exagen Diagnostics, a prognostic testing company, has named Suzanne Mattingly, Ph.D., to the position of VP of business development and marketing. In this role, she establishes strategic business relationships with reference laboratories and pharmaceutical companies to develop and commercialize new sets of genomic markers for diagnostic testing and drug development.

She joins Exagen, Albuquerque, N.M., with 20 years of life-sciences experience in marketing and business development. Most recently, she was VP of marketing at Fast Track Systems.

Dr. Mattingly holds a Ph.D. in microbiology/virology from the Medical College of Virginia and was a postdoctoral fellow in molecular biology at the Fred Hutchinson Cancer Research Center and at UC Berkeley.

Generic **POOL**

Dr. Shankar
HARIHARAN

Par Pharmaceutical Creates Chief Scientific Officer Position

Par Pharmaceutical Companies has appointed Shankar Hariharan, Ph.D., executive VP and chief scientific officer. The company, located in Spring Valley, N.Y., develops, manufactures, and markets generic pharmaceuticals through its principal subsidiary, Par Pharmaceutical. Dr. Hariharan, 47, is responsible for research and development, scientific and regulatory affairs, and quality assurance.

Most recently, Dr. Hariharan served as senior VP at Forest Research Institute.

He received his Ph.D. in pharmaceutical sciences from Northeastern University.

Margaret A. **MCKENNA**

Mylan Names Chief Business Development Officer

Mylan Laboratories has appointed Margaret A. McKenna to the newly created position of chief business development officer. Mylan Laboratories, Canonsburg, Pa., is a pharmaceutical company with four subsidiaries that develop, manufacture, and market an extensive line of generic and proprietary products.

Ms. McKenna has had an extensive career in healthcare-focused corporate finance, having worked for Salomon Smith Barney, ING Barings, UBS Securities, and JP Morgan. Most recently, she was an independent strategic consultant for specialty pharmaceutical and biotech companies

Discovery **POOL**

Dr. Thomas A. **PITLER**

Dr. Charles A.

RITROVATO

Neurogen Announces Executive Promotions

Neurogen, a small-molecule drug discovery and development company located in Branford, Conn., has promoted Thomas A. Pitler, Ph.D., to VP of business development and Charles A. Ritrovato, Pharm.D., to senior VP of drug development and regulatory affairs.

Dr. Pitler is responsible for identifying and securing business opportunities, including collaborative partnerships and the acquisition of technology and assets. He also is responsible for alliance management. Dr. Pitler joined Neurogen in 1995. Previously, he was on the faculty of the University of Maryland School of Medicine.

He holds a B.A. in biology from Wake Forest University and a Ph.D. in physiology from the Bowman Gray School of Medicine, and he received postdoctoral training, supported by a National Institutes of Health fellowship, at the University of Maryland School of Medicine.

Dr. Ritrovato joined Neurogen in 2002 as VP of drug regulatory affairs. He previously served as senior director and global therapeutic area leader for central nervous system and pain drug candidates at Pfizer Global Research & Development, Worldwide Regulatory Affairs.

He holds a B.S. degree in pharmacy from the University of Connecticut and a doctor of pharmacy degree from the University of Rhode Island.

Emerging **POOL**

Charles N. **BLITZER**

Fulcrum Pharmaceuticals Appoints President and CEO



Fulcrum Pharmaceuticals, Las Vegas, a privately held drug design and development company, has named Charles N. (Chuck) Blitzer president and CEO. Most recently, he was chairman and CEO of MGI Pharma.

Mr. Blitzer received a bachelor of science degree from the University of Toledo's School of Pharmacy, a juris doctor from American University's Washington College of Law, and a MBA from Rockhurst College.

Dr. Stephen A. **MARTIN**

Beyond Genomics Fills Chief Technical Officer Position

Stephen A. Martin, Ph.D., has joined Beyond Genomics, Waltham, Mass., as senior VP and chief technical officer. Beyond Genomics applies its proprietary systems biology platforms to develop novel therapeutics and biomarkers. Dr. Martin is responsible for the continued development and integration of the company's molecular systems biology platforms.

Dr. Martin, who has more than 23 years experience in life-sciences research, has joined the company from Applied Biosystems, where he was senior director of the discovery proteomics and small-molecule research center.

He received a B.A. in chemistry from Boston University and a Ph.D. in analytical chemistry from MIT.

Raul **RODRIGUEZ**

Rigel Appoints Executive VP and Chief Operating Officer



Rigel Pharmaceuticals has named Raul Rodriguez executive VP and chief operating officer. Rigel, South San Francisco, Calif., has a mission to become a source of novel, small-molecule drugs to address

large, unmet medical needs. Mr. Rodriguez has been with Rigel for more than four years, most recently serving as senior VP of business development and commercial operations.

He received a bachelor's degree with honors

from Harvard College, a master's of public health from the University of Illinois, and a MBA from the Stanford Graduate School of Business.

CRO POOL

Traci **ADDISON**

Director, Strategic Accounts
Appointed at Kendle

Kendle International, Cincinnati, a global full-service clinical research organization, has promoted Traci Addison to director of strategic accounts. Ms. Addison is responsible for strengthening existing partnerships and expanding strategic alliances with key international biopharmaceutical customers.

She earned her master's degree in audiology and her bachelor's degree in communications disorders from the University of Cincinnati.

Francis **CASIERI**

Dr. Steadman

HARRISON

Colin **SHANNON**

PPD Adds to Senior Staff

PPD, Wilmington, N.C., a leading global provider of discovery and development services and products for pharmaceutical, biotechnology, and medical-device companies, has announced several appointments.

Francis (Frank) Casieri, who was serving as general manager for key accounts, has added senior VP of global business development to his responsibilities following the departure of Richard Staub, who joined PharmaLinkFHI.

Mr. Casieri previously served in this capacity before retiring in spring 2002. Mr. Casieri rejoined PPD in fall 2003 to oversee the company's key accounts.



Steadman Harrison, Ph.D., has been named senior research director and executive director of research and development of Piedmont Research Center, the company's preclinical cancer research division.

Dr. Harrison directs the laboratories and leads a specialized team of scientists in conducting evaluations of anticancer therapies.

Previously, Dr. Harrison served as execu-

tive director of experimental medicine and executive director of business development at EMD Pharmaceuticals.

He holds a doctorate in pharmacology from Indiana University, a B.S. degree from Mississippi State University, and a M.S. degree in organic chemistry from Indiana University.



Colin Shannon has been named to the newly created position of executive VP of global clinical operations. In this role, Mr. Shannon oversees clinical, biostatistics, and data-management operations worldwide.

Mr. Shannon joined PPD in 1995, and for the past four years has served as chief operating officer for the company's European operations.

He holds a master's in business administration from City University in London and a certification as an accountant by the Association of Chartered Certified Accountants.

Dr. Barbara **COLLINS**


Dr. Samer E. **KABA**

Dr. Wendy **MARTIN**

Brian **ROBERTS**

PRA International Adds to Staff

PRA International, a clinical research organization based in McLean, Va., has added to its senior-management team.



Barbara Collins, Ph.D., C. Psych, has been named director, global product development services (GPDS), CNS. Dr. Collins continues to hold the position of clinical professor at the University of Ottawa, School of Psychology. She works out of PRA's Ottawa, Canada, office.



Samer E. Kaba, M.D., has been named senior director, GPDS, CNS. Dr. Kaba is a board-certified neurologist with additional fellowship training in multiple sclerosis and neuro-oncology. Dr. Kaba retains an adjunct faculty position at Emory University and is based at PRA's headquarters.



Wendy Martin, M.D., has been named VP of GPDS, CNS. Dr. Martin is a Duke Univer-

sity-trained neurologist who has more than 12 years of experience as a pharmaceutical physician in big pharma, specialty pharma, and a small start-up company. Dr. Martin is based at PRA's San Diego office.



Brian Roberts, MBA, has been named VP of marketing and is heading all of PRA's marketing efforts, including branding, advertising, Website, public relations, customer surveys, and trade shows worldwide.

Casey **GREENZWEIG**

Michael **JALBOOT**

Chiltern Expands U.S. East Coast Team

Chiltern International, London, has appointed two new business development executives to its east coast operation to spur business growth in the United States. The company has U.S. offices in Atlanta, Austin, Texas, and San Diego. Casey Greenzweig and Michael Jalboot have both joined the company's Atlanta office and are working to build and maintain relationships with existing and new clients in the U.S. biopharmaceutical sectors.

Steve **MATHESON**

Pharmaceutical Profiles
Strengthens U.S. Presence



Pharmaceutical Profiles has appointed Steve Matheson as North American VP of business development. Pharmaceutical Profiles, Nottingham, U.K., is a niche CRO focused on preclinical and Phase I/IIa trials.

Based in Kansas City, Kan., Mr. Matheson represents Pharmaceutical Profiles in the United States and Canada.

He has joined the company from Quintiles, where most recently he was senior director of preclinical business development.

Richard **STAUB**

PharmaLinkFHI Names
President and COO

PharmaLinkFHI has appointed Richard Staub president and chief operating officer of PharmaLinkFHI, an e-clinical research organization based in Research Triangle Park, N.C.

Mr. Staub most recently was senior VP of global business development at PPD.

Service **POOL**

Thomas S. **GUINTER**

Octagon Research Solutions
Names Clinical Information
Management VP

Octagon Research Solutions, King of Prussia, Pa., a provider of regulatory, clinical-information management, process, and information-technology products and services to the life-sciences industry, has named Thomas S. Guinter VP of clinical-information management.

Mr. Guinter is responsible for the development, expansion, and execution of Octagon's clinical-information management services, including all data management, medical writing, and statistical programming offerings. He also guides CDISC and HL7 RCRIM standardization initiatives.

Most recently, he was a senior manager of electronic submissions at Sanofi-Synthelabo Research.

Y. Renee **LEWIS**

Galt Appoints CEO



Galt Associates, Sterling, Va., an international provider of clinical and drug safety solutions, has appointed Y. Renee Lewis as CEO.

As the former chief operating officer of DrugLogic, Ms. Lewis has more than 19 years of experience in operations, management, business, and product development. She is using her expertise in Web-enabled solutions and technology adoption to propel Galt into new markets.

Galt's former President and CEO, Tim Howard, remains on the company's board.

Stephanie **MCGINTY**

Taylor Search Partners
Announces Staff Promotion

Taylor Search Partners, an executive recruitment firm specializing in placing marketing executives in the healthcare and pharmaceutical industries, has promoted Stephanie McGinty to senior search consultant in the Tiro Group.

Ms. McGinty joined the Columbus, Ohio-based company in March 2001. She is responsible for conducting specialized searches for



business development in the pharmaceutical and healthcare industries.

She holds a master's degree in communications from Michigan State University and a bachelor's degree from Ohio University.

Contract-Sales **POOL**

Michelene **ASSAD**

Andrew **BALDWIN**

John **CANVIN**

Vincent **FERNICOLA**

Gary **FISHER**

Terry **HERRING**

Bryan **HORVEATH**

Sandra **JENNINGS**

Pete **MARCHESINI**

Paul **MIGNON**

Tom **SOTTILE**

Ventiv Reorganizes
Through Promotions

Ventiv Health, Somerset, N.J., a provider of customized sales, marketing, and compliance solutions for the pharmaceutical and biotech industries has announced several promotions.

Michelene Assad has been promoted to director of sales analysis and reporting.

Andrew Baldwin has been named senior director of information technology/network services.

John Canvin has been promoted to director of audits and compliance.

Vincent Fernicola has been promoted to senior director of electronic data management.

Gary Fisher has been promoted to senior director, in the Professional Development Group.



Terry Herring has been promoted to president and chief operating officer of Ventiv Pharma Services, focusing on continued business growth through further develop-

ment of the sales, marketing, and clinical support services in the Ventiv Pharma Services portfolio. Mr. Herring joined Ventiv in 1999 and has served as president of Ventiv US Sales since 2002.

Bryan Horveath has been promoted to senior director of client training and development.



Sandra Jennings has been promoted to senior director of sales, assuming leadership for several specialty business sales units. Ms. Jennings has been with Ventiv for seven years, most recently serving as national

business director.

Pete Marchesini has been promoted to the role of executive director/general manager of training and development, which encompasses the Ventiv Professional Development Group (PDG), Client Sales Training, Leadership Development, and Ventiv Academy.

Paul Mignon has been promoted to executive VP of the sales and marketing teams. In this new role, his responsibilities have been expanded to include leadership of the entire Ventiv sales organization. Mr. Mignon joined Ventiv in 2003 as senior VP of business development and marketing.



Tom Sottile has been promoted to VP of operations for Ventiv Pharma Services. He joined Ventiv in 2002 as executive director of operations for Ventiv US Sales and was later promoted to VP.

Mr. Sottile continues to have responsibility for Ventiv Pharma Services operations. He also serves as the Ventiv business development liaison with The Franklin Group, a recent Ventiv acquisition.

Medical-Education **POOL**

Matthew **FRESE**

Dr. George **MAMMEN**

DiMedix Announces Hire
and Promotion

DiMedix, the CME division of Phoenix Group Holdings, has hired Matthew Frese as CME alliance manager. In this new role, he forms partnerships with academic groups and associations.

Mr. Frese previously was at the University of Medicine and Dentistry of New Jersey, where



he directed CME projects and coordinated accreditation requirements.

A graduate of Quinnipiac University, Mr. Frese holds a MBA and a B.A. in psychology. He is a member of the Alliance for CME.



The company also has promoted George Mammen, Ph.D., to the newly created position of senior VP and general manager.

Dr. Mammen, who joined the firm in 2003 to set up the CME division, previously was VP of strategic planning and development.

Dr. Mammen, 43, holds a doctorate in pharmacology from Monash University and a MBA from Deakin University.

Gisela PAULSEN

Stacey SINGER

Health Learning Systems Names President and General Manager

Health Learning Systems (HLS), CommonHealth's founding medical-education unit located in Wayne, N.J., has promoted Gisela Paulsen, M.Pharm., to general manager and has named Stacey Singer president.



Ms. Paulsen had been executive VP, managing director. In this new role, she is responsible for both client services and operations at HLS.

Ms. Paulsen joined HLS in October 2003 from Vox Medica, where she was senior VP of marketing and business development and executive VP and board of director of Vox Medica Europe.



Ms. Singer began her career at CommonHealth in 1988 as a senior account executive at Thomas Ferguson Associates. Most recently, she was president of MBS/Vox, CommonHealth's research-based consultancy.

Laurie SCHÄFER

Princeton Partners Appoints Managing Director for DevCom Group

Laurie Schäfer has been named managing director of DevCom Group, Princeton, N.J., a



subsidiary of Princeton Partners. Ms. Schäfer is responsible for leading DevCom, a boutique agency that develops clinically relevant medical education and patient education materials with unique brand solutions

for healthcare clients.

Before joining the agency, she served as VP and account supervisor at Integrated Communications. Ms. Schäfer has a B.A. from SUNY College at Old Westbury.

Technology/Web POOL

Michele LENTZ

Group DCA Promotes to Fill VP of Client Services Position



Group DCA, an online healthcare communications company located in Montclair, N.J., has promoted Michele Lentz to VP of client services.

In this role, Ms. Lentz is focused on customer-relationship building, business development, and corporate initiatives that benefit clients through efficiencies, enhanced product offerings, and maximized results.

She joined Group DCA in 2002 as senior account director.

Ms. Lentz received her B.S. in business administration/marketing from Kutztown University.

Association POOL

Dr. Jeff MACKIE

CMR Institute Board Appoints Chairman

Jeff Mackie, Ph.D., founder/owner of Mackie and Associates, has been named chairman of the Certified Medical Representatives Institute board. CMR Institute is an independent, nonprofit educational organization located in Roanoke, Va.

Dr. Mackie replaces Thomas P. Reinders,

Pharm.D., associate dean of the School of Pharmacy for Virginia Commonwealth University, who steps down after almost 20 years of service to the institute, the last nine as board chairman.

Dr. Mackie brings more than 20 years of experience in the pharmaceutical industry and 10 years of experience serving on CMR Institute's board. He is former chairman of the CMR Institute Curriculum Committee and a member of the American Pharmaceutical Association and the National Speakers Association. Dr. Mackie is a registered pharmacist with a background in managing and providing technical, sales, and management/personal development training.

Dr. John C. NELSON

New AMA President To Advocate for Patients and Champion Professionalism in Medicine

John C. Nelson, M.D., M.P.H., has been named the 159th president of the American Medical Association, Chicago, the nation's largest physician organization.

Dr. Nelson, an obstetrician-gynecologist, plans to work to overcome the mounting challenges affecting healthcare, such as providing health insurance coverage to the uninsured, reforming the medical liability system, and strengthening Medicare.

Dr. Nelson was elected to the AMA's board of trustees in 1994 and served as secretary-treasurer in 2002. During his term, Dr. Nelson will continue to see patients on a limited basis while he advocates the AMA's efforts to improve the healthcare system.

Media POOL

Maureen Dwyer

LIBERTI

Monthly Prescribing Reference Hires Senior Account Manager

Maureen Dwyer Liberti has been brought on board as senior account manager at Prescribing Reference/Haymarket Media, publisher of Monthly Prescribing Reference (MPR) and specialist editions for PAs and NPs, pediatricians, ob/gyns, and residents.

Most recently, she was the media director of the advertising group at Johnson & Johnson. Her responsibilities include MPR, all specialty editions, and the development and sales of customized PRI products and projects.

She is based in the New York office.

Dr. John C. **MARLOW**
Chief Medical Officer Role Created
at Advanstar Medical Economics



Advanstar Communications has named John C. Marlow, M.D., chief medical officer of Advanstar Medical Economics, New York. The division offers a wide range of strategic health-care information distributed through multimedia channels.

In this newly created role, Dr. Marlow is charged with creating and leading a medical affairs department within Advanstar Medical Economics.

His responsibilities include active participation in the sales, marketing, and business development efforts, participation in product development, as well as directing and overseeing content for medical education programs and new products for Advanstar Medical Economics' customer base.

Most recently, Dr. Marlow was VP of content for Medsn where he was responsible for designing medical-education, e-learning, and pharma-related medical programs.

Dr. Marlow holds a doctor of medicine degree from the University of Texas Health Science Center in Houston.

He has more than eight years clinical-medical experience in both managed-care and private practice settings.

Agency **POOL**

Christine **DRUMHELLER**

Randi **JARRATT**

W. Anne **KREPACKI**

Erin **POWELL**

Kortney **RAGINS**


Heather **TRAUM**

DMW Adds to Account and
Creative Services Teams

DMW, a full-service direct response advertising agency with offices in Wayne, Pa., and Plymouth, Mass., has made additions to its staff.



Christine Drumheller has been hired as senior account supervisor. Before joining DMW, she served in successive account management roles, most recently as senior account manager for Euro RSCG Devon Direct.



Randi Jarratt has joined DMW's creative department as art director. Her experience includes graphic arts work for Aramark, Aetna, and Briggs Communications.



W. Anne Krepacki has joined the agency as a senior account supervisor. Most recently, she served as a marketing consultant, directing marketing programs for Marsh Affinity Group Services.



Erin Powell has joined the team as an account executive. Her experience includes serving as an account manager for Delaware Marketing Group.



Kortney Ragins has joined DMW as an

account supervisor.

Heather Traum has joined DMW as an account executive. Most recently, she was an account executive at Harte-Hanks Direct, where her clients included various healthcare and Blue Cross and Blue

Shield plans.

Roberta **JARET**

Michael **STUTTMAN**

Frank **ZSOLDOS**

GSW Worldwide's New York Office
Announces Executive Level Staff

GSW Worldwide, a full-service healthcare advertising agency based in Columbus, Ohio, has added staff to its New York office. GSW Worldwide is a subsidiary of inChord Communications.

Roberta Jaret has been named senior art director. She is responsible for the concept, design, presentation, execution, and produc-

tion of all assigned projects. Before GSW Worldwide, Ms. Jaret was the owner/art director of Roberta Jaret Design. She holds a bachelor's degree from the New York Institute of Technology.

Michael Stuttman has been named VP/account director. He is responsible for managing and leading one of GSW Worldwide's pharmaceutical accounts. Previously he served as managing director at McNichols Stuttman Group. He holds a bachelor's degree from the University of Colorado.

Frank Zsoldos has been named associate creative director. He is responsible for overseeing all creative development for one of GSW Worldwide's consumer accounts. Before GSW Worldwide, he served as group creative director at Grey Direct West. Mr. Zsoldos holds a bachelor's degree from Columbia University.

Henry **LEE**
Pacific Communications Names
VP for Recently Acquired
Botox Business

Pacific Communications has hired Henry Lee as VP, management supervisor, for the agency's newly acquired Botox business from Allergan. Based in Costa Mesa, Calif., Pacific Communications is a full-service provider of integrated healthcare communications.

Mr. Lee most recently ran the Novartis business at Cline Davis Mann.

He is a graduate from the United States Military Academy at West Point with honors.

Shana **ROBINSON**
Karen **SUN**

Donahoe Purohit Miller Hires
and Promotes

Donahoe Purohit Miller (DPM), a full-service healthcare marketing and communications company, has announced new hires and a promotion.

Shana Robinson has been promoted to brand account supervisor. Her responsibilities include seeking out new opportunities to expand agency business with existing clients and pursuing new business.

Ms. Robinson joined DPM as a senior account executive in 2002.

Karen Sun has been hired as assistant account executive at DPM Advertising. She previously was an account coordinator for a marketing communications company and client service manager at TMP Worldwide.

Please send your personnel announcements to
feedback@pharmavoices.com.